

NOVEL IMMUNOTHERAPEUTICS *summit* 2015

Includes the three co-located conferences:

13th Cytokines & Inflammation
7th Immunotherapeutics & Immunomonitoring
3rd Immunogenicity & Immunomonitoring

JANUARY 29-30, 2015 • SAN DIEGO, CA

Platinum Sponsors:



Gold Sponsors:



Media Partners:



Visit www.gtcbio.com for more information!

ABOUT

GTCbio is proud to present the [Novel Immunotherapeutics Summit 2015](#), to be held in **San Diego, CA** on **January 29-30, 2015**. The summit will bring together our usual balance of industry and academia, so that delegates have the unique opportunity to network with colleagues from different sectors and gain fresh perspective on the various research happening on complementary areas of the latest breakthroughs in the immunology field.

The Summit includes three concurrent conferences:

[13th Cytokines & Inflammation](#)

This meeting provides a forum for researchers to discuss the latest advances in targeting cytokines and chemokines for therapeutic interventions, cytokines and metabolism, and cytokines signaling pathways.



[7th Immunotherapeutics & Immunomonitoring](#)

Leading experts will cover recent advances in immunotherapy and how they relate to various immunotherapy modalities, specific cancers, cell subsets, animal models, and tumor microenvironment.

[3rd Immunogenicity and Immunotoxicity](#)

Delegates will learn about ongoing research for tools to mitigate risks associated with the immunogenicity of therapeutic proteins.

2014 DEMOGRAPHICS



SPONSORSHIP OPPORTUNITIES

Connect with high level professionals and renowned scientists in academia within the field in an intimate and highly interactive environment. We are expecting over 300 attendees for the entire Novel Immunotherapeutics Summit 2015.

- Option to receive the delegate list a week before and a week after the conference.
- Exhibit space is shared between all conferences, providing you access to delegates at all conferences.
- Exhibitors are located in the same room where all networking functions take place. The coffee, snack stations, breakfast, and reception all occur in this room.
- Your corporate logo will be placed on the cover page of the conference brochures, the USB proceedings given to all conference delegates, and on the presentation screen during all breaks to enhance your company's visibility at the event. Your logo will also be placed on the conference website agenda linked to your website.

For sponsorship and exhibit opportunities, please contact:

Amber Kempf
Account Executive
amber.kempf@gtcbio.com

Steve Holmstrom
Account Executive
steve.holmstrom@gtcbio.com

SPONSORS

PLATINUM



Caprion/Immunecarta is specialized in the design and implementation of immune monitoring assays to assess the phenotypic and functional profiles of immune responses in both pre-clinical and clinical settings (under GLP). We are also leader in Proteomic for the discovery and validation of predictive and prognostic biomarkers using mass spectrometry to rapidly measure the differential expression of proteins from small amounts of biological fluids, tissue, cells and organelles.

Founded in 2007, **Quanterix** offers an ultra-sensitive diagnostic platform capable of measuring individual proteins at concentrations 1000 times lower than the best immunoassays available today. The Single Molecule Array (Simoa™) technology at the heart of the platform enables the detection and quantification of biomarkers previously difficult or impossible to measure.

Quanterix™



ACEA Biosciences, Inc. is a pioneer in the development and commercialization of high-performance microelectronic systems for cell-based assays. ACEA's xCELLigence® systems are widely used in academic labs, government institutions, biotech and pharma companies around the world to study cell adhesion, cell migration/invasion, GPCR/RTK signaling, cell proliferation and compound/cell/viral-mediated cytotoxicity.



Singulex®

GOLD



Myriad RBM, Inc. is the world's leading multiplexed immunoassay testing laboratory, providing comprehensive protein biomarker services based on its Multi-Analyte Profiling (MAP) technology platform. This platform provides pre-clinical and clinical researchers with reproducible and quantitative data for a few or hundreds of proteins in a cost-effective manner.

Over the past 25 years, **PeproTech** has grown into a global enterprise manufacturing an extensive line of Recombinant Human, Murine and Rat Proteins, Animal-Free Recombinant Proteins, Monoclonal Antibodies, Affinity Purified Polyclonal Antibodies, Affinity Purified Biotinylated Polyclonal Antibodies, ELISA Development Kits, Cytokine Packages and Cell Culture Media Products.



SPONSORS

GOLD

Immudex manufactures MHC Dextramers, the leading MHC multimer reagent for the detection of antigen-specific T cells for research and in vitro diagnostics. Under an agreement with the US Cancer Immunotherapy Consortium (CIC) and the European Cancer Immunotherapy Consortium (CIMT), Immudex also provides MHC Multimer and Elispot proficiency panel services worldwide.



PBL Assay Science's ultra-sensitive biomarker detection services, low-picogram IFN ELISAs, customizable Multiplex ELISAs, cell-based activity testing, and high quality protein & antibody reagents are ready to expedite your research results. You can depend upon our 25 years in reliable assay development to help you solve your most difficult problems.

AllCells is a global biotechnology partner dedicated to improving research. We provide hematopoietic, immunological tissue and primary cell types for research around the world. Our large selection of healthy, diseased cells, animal cells, and bioservices help accelerate research and allow scientists to focus on results.



eBioscience, an **Affymetrix** company, develops and manufactures over 11,000 high-quality antibodies, recombinant proteins, immunoassays and multiplex assays at ISO-certified facilities worldwide for research and clinical use that accelerate scientific discovery in the areas of immunology and oncology.

PolyPeptide Group is a leading provider of custom and generic peptides for research and pharmaceutical applications with 6 facilities worldwide. Our focus is on proprietary and generic GMP-grade peptides for the pharmaceutical and biotechnological market. We are committed to the highest quality peptide manufacturing for every stage of product development.



Randox Pharma Sciences has over 30 years' experience as an innovative diagnostic manufacturer supplying the world's top CRO's, biopharmaceutical and research organisations. Our novel multiplex protein analyzers, based on our proprietary Biochip Array Technology, include a comprehensive menu of cytokines across five multi-analyte arrays. Our biochips are also fully customizable. This impressive portfolio is complemented by an extensive range of clinical chemistry analysers, diagnostic reagents and customized QC.

AGENDA AT-A-GLANCE

Day 1 - Thursday, January 29, 2015

7:00a *Registration & Continental Breakfast*

7:55a *Welcome & Opening Remarks | Break into Individual Conferences*

	13th Cytokines & Inflammation	7th Immunotherapeutics & Immunomonitoring	3rd Immunogenicity & Immunotoxicity
8:00a	Session I Metabolism, Cytokines and Immunity	Session I Disease & Tumor Microenvironment Session II Novel Targets in Immune Therapeutics	KEYNOTE PRESENTATION <i>Alessandro Sette</i> La Jolla Institute for Allergy & Immunology (LJI) Session I Computational Methods for Immunogenicity Evaluation
10:00a	<i>Morning Networking & Refreshment Break</i>		
10:30a	Session II Cytokines and the Impact of the Microbiome	Session II Novel Targets in Immune Therapeutics (cont.) Session III Novel Therapeutic Approaches	Session II Immunogenicity Assessment for Peptide Therapeutics
12:35p	<i>Lunch on Your Own</i>		
2:05p	Session III Cytokines and Cancer Immunotherapy	Session III Novel Therapeutic Approaches (cont.)	Session III Immunotoxicity & Drug Hypersensitivity Session IV Immunogenicity Assessment for Biosimilars
3:45p	<i>Afternoon Networking & Refreshment Break</i>		
4:15p	Session IV Advances in Innate and Adaptive Immunity	Session IV Immunomonitoring	Session IV Immunogenicity Assessment for Biosimilars (cont.) Session V Immunotoxicity Evaluation of Novel Drug Candidates
5:55p	<i>Networking Reception & Poster Session</i>		

All times are approximate and subject to changes without notice

AGENDA AT-A-GLANCE

Day 2 - Friday, January 30, 2015

7:30a Registration & Continental Breakfast

7:55a Welcome & Opening Remarks

Plenary Keynote Session

8:00a
Title TBA
George Yancopoulos, Chief Scientific Officer, **Regeneron**
Accelerating Translation of Novel Immunotherapeutics with Rapid Go-No Go Study Designs
Francisco Leon, Vice President, Translational Medicine, Immunology Development, **Janssen R&D**
Follicular Helper T Cells (Tfh) Cells and Antibody Responses in Health and Disease
Shane Crotty, Professor, Vaccine Discovery, **La Jolla Institute for Allergy & Immunology (LJI)**

10:00a Morning Networking & Coffee Break

Break into Individual Conferences

13th Cytokines
& Inflammation

7th Immunotherapeutics
& Immunomonitoring

3rd Immunogenicity
& Immunotoxicity

10:45a Session V
Targeting Cytokines & Chemokines for
Therapeutic Interventions

Session IV
Combinatorial Immunotherapies

Session VI
Protein Aggregation, Biological Activity
& Immunogenicity

12:30p Lunch Provided by GTC

Conference Concludes

Session IV
Combinatorial Immunotherapies (cont.)

Conference Concludes

1:35p

2:50p

Conference Concludes

All times are approximate and subject to changes without notice

PLENARY KEYNOTE SPEAKERS



Follicular Helper T Cells (Tfh) Cells and Antibody Responses in Health and Disease
Shane Crotty, Professor, Vaccine Discovery, **La Jolla Institute for Allergy & Immunology (LJI)**

Dr. Crotty received his B.S. in Biology from MIT and his PhD in molecular biology at University of California, San Francisco. After working on an AIDS vaccine for several years, Dr. Crotty came to the decision that we do not know the immunology we need to know for rational vaccine design. Therefore, his focus since that point has been taken the steps necessary to build fundamental immunology knowledge necessary for future rational vaccine design. The Crotty lab focuses on understanding the mechanisms regulating the immunological basis of high quality antibody responses. The Crotty laboratory at LJI has focused on the important roles of CD4 T cells in these processes. CD4 T cells are essential for B cell help, germinal center development, and the generation of affinity matured memory B cells and long-lived plasma cells. The Crotty lab has helped established that follicular helper T cells (Tfh) are a distinct type of differentiated CD4 T cell uniquely specialized in B cell help, and that Tfh differentiation is controlled by the transcription factor Bcl6 (Science '09). He has made major advances in the area of T cell help to B cells, and through this work has become an internationally recognized leader in the field of Tfh cell biology (Annual Review of Immunology '11). Dr. Crotty was named a Pew Scholar in Biomedical Sciences in 2005, and was the recipient of the annual American Association of Immunologists (AAI) Investigator Award for outstanding early-career research contributions to the field of Immunology in 2012.



Accelerating Translation of Novel Immunotherapeutics with Rapid Go-No Go Study Designs
Francisco Leon, Vice President, Translational Medicine, Immunology Development, **Janssen R&D**

Francisco Leon, MD PhD, Vice President and Head of Immunology Translational Medicine at Janssen R&D, Pharmaceutical Companies of Johnson & Johnson, is a clinical immunologist who received his MD from Autónoma University in Madrid, Spain and received clinical training at the Ramon y Cajal and La Paz hospitals in Madrid. As a basic immunologist, he worked at the University of Tromsø (Norway), Autónoma University of Madrid and the Laboratory of Clinical Investigation/Laboratory of Molecular Immunology, NIAID, NIH (Bethesda, MD). The focus of his basic research was mucosal immunology and, in particular, celiac disease and inflammatory bowel disease. In the Biotech and Pharmaceutical Industry, Francisco Leon has focused on early-stage development and translational research in immunologic diseases (rheumatoid arthritis, transplantation, IBD, psoriasis, celiac disease, asthma, etc) in Bristol-Myers Squibb, MedImmune, Alba Therapeutics and Centocor/Janssen. Francisco is also Adjunct Research Associate Professor of Medicine at Jefferson Medical College (Philadelphia). He has authored or co-authored >60 peer-reviewed articles and book chapters as well as several patents.



George Yancopoulos, Chief Scientific Officer, **Regeneron**

George D. Yancopoulos, M.D., Ph.D., joined the Company in 1989 as its Founding Scientist and is currently President, Regeneron Laboratories and Chief Scientific Officer. He received his M.D. and Ph.D. from Columbia University. Dr. Yancopoulos was the 11th most highly cited scientist in the world in the 1990s, and in 2004 he was elected to be a member of the National Academy of Sciences. Dr. Yancopoulos, together with key members of his team, is a principal inventor and developer of Regeneron's three FDA-approved drugs - including EYLEA® (aflibercept) Injection, ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion, and ARCALYST® (rilonacept) Injection - as well as of its foundation technologies including the TRAP technology, VelociGene®, and VelociImmune®.

DISTINGUISHED SPEAKERS



Session: Metabolism, Cytokines and Immunity

Vivian Albert
Celgene Cellular Therapeutics



TLR Dependent Activation of the Innate Immune System for Cancer Immunotherapy

Dennis Klinman
National Cancer Institute, NIH



A Live-Cell Imaging Approach to Quantitating T-Cell and Neutrophil Chemotaxis in Real-Time

Daniel Appledorn
Essen BioScience



Session: Advances in Innate and Adaptive Immunity

Michael Lotze
University of Pittsburgh School of Medicine



The Potential of Interleukin-2 (IL-2) Immunotherapy to Deplete T Follicular Helper Cells and Treat Autoimmune Disease

Andre Ballesteros-Tato
University of Alabama, Birmingham



Evaluation of TNFR2 as a Target of Checkpoint Inhibition

Joost J. Oppenheim
National Cancer Institute, NIH



TGF-beta Blockade in Cancer Immunotherapy

Jay Berzofsky
National Cancer Institute, NIH



Session: Cytokines and the Impact of the Microbiome

Kevin Peters
Aerpio Therapeutics



Intersection of Caspase and Autophagy Pathways in Crohn's Disease

Menno van Lookeren Campagne
Genentech




Session: Cytokines and Cancer Immunotherapy

Theresa Torres Pizarro
Case Western Reserve University



Concurrent Targeting of Functionally Redundant Th1 and Th17 Responses in CNS Autoimmunity

Rachel Caspi
National Eye Institute, NIH



Modulating Plasmacytoid Dendritic Cell Function for Treating Autoimmune Diseases

Dania Rabah
Biogen Idec



Metabolic Control of Regulatory T Cell Function

Hongbo Chi
St. Jude Children's Research Hospital



Session: Targeting Cytokines & Chemokines for Therapeutic Interventions

Antony Symons
Amgen

DISTINGUISHED SPEAKERS (cont.)



Session: Advances in Innate and Adaptive Immunity

Fabio Cominelli
Case Western Reserve University



Regulation of Soluble IL-15 Complexes During Homeostasis and Immune Stimulation

Kimberly Schluns
University of Texas MD Anderson Cancer Center



Adaptive Immunity to Murine Skin Commensals

Scott K. Durum
National Cancer Institute, NIH



Session: Targeting Cytokines & Chemokines for Therapeutic Interventions

Jennifer Towne



Homeostatic IL-23R Signaling Limits TH17 Responses through IL-22-Mediated Containment of Commensal Microbiota

Nico Ghilardi
Genentech



Targeting XIAP in NOD2 Mediated Inflammatory Diseases

Domagoj Vucic
Genentech



Balancing Act: Caspases, RIP Kinases, and Cytokines in Cell Death and Development

Douglas Green
St. Jude Children's Research Hospital



Biomarker Profile in NHP Collagen-Induced Arthritis

Jia Zeng
PharmaLegacy Laboratories (Shanghai)



CSFs Regulate Macrophage Polarization

Thomas Hamilton
Cleveland Clinic



IL-22 and Cancer Stemness

Weiping Zou
University of Michigan School of Medicine



IFN-gamma Regulates mTORC1, Cellular Metabolism and mRNA Translation to Potentiate Inflammatory Macrophage Activation

Lionel Ivashkiv
Hospital for Special Surgery

DISTINGUISHED SPEAKERS



Combination Immunotherapies with CRS-207, a Live-attenuated, Double-deleted (LADD) Listeria Monocytogenes Targeting Mesothelin-expressing Tumors

Dirk Brockstedt
Aduro BioTech




Session: Novel Targets in Immune Therapeutics

Li-Fen Lee
Pfizer



A New Platform for Effective T Cell-mediated Immunomonitoring

Pirouz Daftarian
University of Miami Miller School of Medicine



Promise and Challenges of Immuno-Oncology

Peter Lee
City of Hope Comprehensive Cancer Center



Unlocking Clinical Correlates and Durable Immune Responses Using Multi-color Flow Cytometry in Subjects Treated with Dendritic Cell Immunotherapy

Mark DeBenedette
Argos Therapeutics



Immunotherapy as Personalized Medicine

Ravi Madan
National Cancer Institute, NIH



ImmTACs: Bi-specific T Cell Receptor-anti-CD3 Fusions for Potent Redirected Killing of Cancer Cells

Joseph Dukes
Immunocore



Session: Immunomonitoring

Yoav Peretz
ImmuneCarta Services



Poxvirus-based Active Immunotherapy Combined with Immune Checkpoint Inhibitors for Apparent Clinical Benefit as well as Synergistic Tumor Regression and Extended Survival in Preclinical Models

Alex Franzusoff
Bavarian Nordic



Armed Antibodies for Cancer Therapy

Paul Polakis
Genentech



Blockade of Phosphatidylserine Enhances the Anti-tumor Activity of Targeted Therapy and Immune Checkpoint Inhibitors by Reducing Immunosuppressive Inflammatory Cells in the Tumor Microenvironment

Bruce Freimark
Peregrine Pharmaceuticals



Manipulating the Tumor Microenvironment ex vivo to Optimize TIL for Adoptive Cell Therapy

Laszlo Radvanyi
Lion Biotechnologies



Applications of Genome-scale Profiling in Cancer Immunotherapy


Debraj GuhaThakurta
Dendreon Corporation



eACTTM: Engineering the Immune System with CARs and TCRs to Eradicate Cancer

Margo Roberts
Kite Pharma

DISTINGUISHED SPEAKERS (cont.)



Session: Combinatorial Immunotherapies

Omid Hamid
Los Angeles Clinic and Research Insitute



Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pharmacodynamic Results of a Phase 3, Randomized, Controlled Trial

Peter Schafer
Celgene



The Provocative Issue of Tumor Genomic Heterogeneity in Cancer Vaccine Based Immunotherapy

Michael Hanna Jr.
Vaccinogen



Myeloid Cell PI3Kgamma and BTK as Therapeutic Targets for Solid Tumor

Judith Varner
University of California, San Diego



Session: Immunomonitoring

Ulrich Hoffmueller
Epiontis GmbH



Personalized immunotherapies for Glioma and Pancreatic Cancer

Steffen Walter
Immatics Biotechnologies GmbH



Control and Induction of Immunity by Vector Gene Delivery

Frank Jones
Etubics Corporation



CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-specific T Cells

Xiuli Wang
City of Hope National Medical Center



Predictive Biomarkers for Response to Therapy in IBD

Mary Keir
Genentech



Session: Combinatorial Immunotherapies

Jon Wigginton
MacroGenics



Immune Corrective Strategies for Combinational Cancer Immunotherapy

Samir Khleif
Medical College of Georgia



Adoptive T Cell Therapy of Cancer

Cassian Yee
MD Anderson Cancer Center

KEYNOTE SPEAKER



The Use of the Immune Epitope Database and Analysis Resource to Assist in the Evaluation of Protein Drug Immunogenicity

Alessandro Sette
Professor and Head, Vaccine Discovery
La Jolla Institute for Allergy & Immunology (LJI)

DISTINGUISHED SPEAKERS



Recommendations from the AAPS LBABFG Biosimilars Action Program Committee on the Development and Validation of ADA assays for Biosimilar Drug Development

Michael Anderson
BDS Immunoassay Services



Motifs and Math; Mapping the Multiple Dimensions of Immunogenicity

Jane Homan
EigenBio



Deciphering Cellular Immune Responses to AAV, a Toolkit

Etiena Basner-Tschakarjan
The Children's Hospital of Philadelphia



Session: Computational Methods for Immunogenicity Evaluation

Bette Korber
Los Alamos National Laboratory



Influence of Aggregates on in vitro T Cell Responses

Gary Bembridge
Antitope, an Abzena Company



Immunogenicity Assessment for Biosimilars

Arno Kromminga
IPM Biotech



Session: Computational Methods for Immunogenicity Evaluation

Lawrence Berliner
**University of Denver
Ohio State University**



Excipients - Friends or Foes of Protein/Peptide Drugs?

Harald Kropshofer
F. Hoffmann-La Roche



Session: Immunotoxicity Evaluation of Novel Drug Candidates

Joerg Bluemel
MedImmune



Session: Protein Aggregation, Biological Activity & Immunogenicity

Christian Schoneich
The University of Kansas



Immunogenicity Assays: Challenges of Anti-Drug Antibody (ADA) Detection in the Presence of High Concentration of Circulating Drug (Drug Tolerance)


Xiao-Yan Cai
Merck



An Integrated Approach to Managing Immunogenicity Risk and Drug Immune Modulation

Nikolai Schwabe
ProlImmune Limited

DISTINGUISHED SPEAKERS (cont.)



*Inducing Immunologic Tolerance in vivo
by Targeting Antigens to Plasmacytoid
Dendritic Cells*

Edward A. Clark
University of Washington



*Recommendations from the AAPS
Biosimilars Focus Group Committee
on the Development and Validation
of Neutralization Antibody assays for
Biosimilar Drug Development"*

Dominique Gouty
BioAgilytix



*Anti-Drug Antibody Immunoassays:
Nuances for a Peptide Therapeutic*

M. Benjamin Hock
Amgen



*Understanding the Immunogenicity Risk
of Therapeutic Proteins Attributed to
Product Molecular Properties*

Li Xue
Pfizer



*Session: Immunogenicity Assessment for
Peptide Therapeutics*

Qing (Joe) Zhou
Allergan



TBA
Thermo Fisher Scientific

CONFERENCE DETAILS

REGISTRATION

Early Registration Discount:

10% until December 29, 2014

Register for 2 the 3rd goes FREE with coupon code: **RCDVB**

To register online, visit: www.gtcbio.com/register/immunotherapeutics-summit

	Commercial	Academic / Govt	Student
Summit	2095.00	1095.00	945.00
Individual Conference	1895.00	895.00	745.00

CALL FOR PAPERS

To be considered for a short oral presentation, please submit an abstract by **December 29, 2014**. Selected presentations will be based on quality of abstract and availability. Selected abstracts will be notified via email or telephone 2-3 weeks before the conference. Presentation slots fill up fast so please submit your abstract soon.

Click on the following conferences to submit an abstract:

[13th Cytokines & Inflammation](#)

[7th Immunotherapeutics & Immunomonitoring](#)

[3rd Immunogenicity & Immunotoxicity](#)

VENUE

Paradise Point Resort & Spa

1404 Vacation Road
San Diego, CA 92109
858-581-5900

Discounted Group Rate: \$199.00 per night

Discount Deadline: January 2, 2015

Toll Free Reservations: 800-344-2626

Mention GTCJAN2015 to receive the group rate.

Online Reservations:

<https://gc.synxis.com/rez.aspx?Hotel=29066&Chain=5156&arrive=1/26/2015&depart=2/3/2015&adult=1&child=0&group=GTCJAN2015>



PROCEEDINGS

If you are unable to attend the conference you can purchase the proceedings by downloading the order form [here](#). Fill out the order form and fax it to 1 (626) 433-4433 or email it to proceedings@gtcbio.com.